Exploring the Design & Preclinical Activity of AZD9592: a Bispecific EGFRMET Targeted ADC
Time: 4:00 pm
day: Conference Day One PM
Details:
- Characterization of internalization and cytotoxic properties of AZD9592, a bispecific ADC designed to selectively bind EGFR and c-MET on tumor cells and deliver a topoisomerase 1 inhibitor payload
- Using in vivo PDX studies to explore relationship of target expression to tumor growth inhibition
- Pharmacodynamic biomarkers supporting multi-faceted mechanism of action
